Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38654883 | 0.86 | SIRT6 (0.33) | CYP2C19 | |
| SCHEMBL31292441 | 0.86 | CYP2C19 (0.39) | DGAT1CYP2C19 | |
| SCHEMBL31292510 | 0.81 | DGAT1 (0.40) | DGAT1 | |
| SCHEMBL38654984 | 0.77 | DGAT1 (0.43) | DGAT1 | |
| SCHEMBL31292191 | 0.76 | DGAT1 (0.37) | DGAT1CYP2C19 | |
| SCHEMBL27940305 | 0.74 | HCAR2 (0.36) | HCAR2 | |
| SCHEMBL11027593 | 0.73 | HCAR2 (0.46) | HCAR2 | |
| SCHEMBL31292560 | 0.72 | MAPT (0.46) | DGAT1 | |
| SCHEMBL38656034 | 0.72 | DGAT1 (0.43) | DGAT1HCAR2 | |
| SCHEMBL31292574 | 0.71 | CYP2C19 (0.40) | DGAT1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099466-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2026-05-15 | — | — | WO | disclosed |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12459920-B2 | Targeted protein degradation | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-04 | — | — | US | disclosed |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| WO-2025024521-A1 | SUBSTITUTED PIPERIDINEDIONES FOR TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | DGAT1 3679/4885HCAR2 1807/4885CYP2C19 4814/4885 |
| US-12459920-B2 | Targeted protein degradation | NEK7, NEK1, RIPK1 | DGAT1 3679/4885HCAR2 1809/4885CYP2C19 4816/4885 |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | DGAT1 3679/4885HCAR2 1807/4885CYP2C19 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.